Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia

Phase 4 Completed 167 enrolled Laboratoire Innotech International

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess, in patients with moderate IDA, the Onset-of-Action of a daily treatment with Tot'Héma®. The onset of action is defined as the time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level.

Timeline

Start: 2020-11-12
Primary completion: 2023-10-06
Completion: 2023-10-06

Publications

Cacoub P, Otieno FO, Trichereau J, Gobert O, Kerveillant AL, Escola J, Verriere F. Early Haematologic Response to Oral Iron Treatment in Adults With Moderate Iron-Deficiency Anaemia. Anemia. 2025 Nov 20;2025:8866390. doi: 10.1155/anem/8866390. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FERROUS GLUCONATE ANHYDROUS	Small molecule	150 mg	Oral
Background	Copper	Unknown	—	Oral
Background	manganese gluconate	Unknown	—	Oral

Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia

Summary

Timeline

Publications

Drugs

Indications